Estimates of the Public Health Impact of a Pediatric Vaccination Program Using an Intranasal Tetravalent Live-Attenuated Influenza Vaccine in Belgium

被引:5
|
作者
Gerlier, Laetitia [1 ]
Lamotte, Mark [1 ]
Mendes, Sofia Dos Santos [2 ]
Damm, Oliver [3 ]
Schwehm, Markus [4 ]
Eichner, Martin [5 ,6 ]
机构
[1] IMS Hlth Real World Evidence Solut, Davos Bldg,Vincilaan 7, B-1935 Zaventem, Belgium
[2] SA AstraZeneca NV, Uccle, Belgium
[3] Univ Bielefeld, Bielefeld, Germany
[4] ExploSYS GmbH, Leinfelden Echterdingen, Germany
[5] Univ Tubingen, Inst Clin Epidemiol & Appl Biometry, Tubingen, Germany
[6] Epimos GmbH, Dusslingen, Germany
关键词
COST-EFFECTIVENESS; YOUNG-CHILDREN; ECONOMIC BURDEN; UNITED-STATES; EFFICACY; ENGLAND; GERMANY; FRANCE; TIME; METAANALYSIS;
D O I
10.1007/s40272-016-0180-6
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objectives Our objectives were to estimate the public health outcomes of vaccinating Belgian children using an intranasal tetravalent live-attenuated influenza vaccine (QLAIV) combined with current coverage of high-risk/elderly individuals using the trivalent inactivated vaccine. Methods We used a deterministic, age-structured, dynamic model to simulate seasonal influenza transmission in the Belgian population under the current coverage or after extending vaccination with QLAIV to healthy children aged 2-17 years. Differential equations describe demographic changes, exposure to infectious individuals, infection recovery, and immunity dynamics. The basic reproduction number (R-0) was calibrated to the observed number of influenza doctor visits/year. Vaccine efficacy was 80 % (live-attenuated) and 59-68 % (inactivated). The 10-year incidence of symptomatic influenza was calculated with different coverage scenarios (add-on to current coverage). Results Model calibration yielded R-0 = 1.1. QLAIV coverage of 75 % of those aged 2-17 years averted 374,000 symptomatic cases/year (57 % of the current number), 244,000 of which were among adults (indirect effect). Vaccinating 75 % of those aged 2-11 years and 50 % of those aged 12-17 years averted 333,200 cases/year (213,000 adult cases/year). Vaccinating only healthy children aged 2-5 years generated direct protection but limited indirect protection, even with 90 % coverage (40,800 averted adult cases/year; -8.4 %). Targeting all children averted twice as many high-risk cases as targeting high-risk children only (8485 vs. 4965/year with 75 % coverage). Sensitivity analyses showed the robustness of results. Conclusions The model highlights the direct and indirect protection benefits when vaccinating healthy children with QLAIV in Belgium. Policies targeting only high-risk individuals or the youngest provide limited herd protection, as school-age children are important influenza vectors in the community.
引用
收藏
页码:303 / 318
页数:16
相关论文
共 50 条
  • [31] Intranasal vaccination with a live-attenuated SARS-CoV-2 vaccine candidate confers potent mucosal and systemic immunity and protection
    Adam, Awadalkareem
    Kalveram, Birte K.
    Zou, Jing
    Rodriguez, Leslie
    Singh, Ankita
    Chen, John Yun-Chung
    Xie, Xuping
    Shi, Pei-Yong
    Wang, Tian
    JOURNAL OF IMMUNOLOGY, 2023, 210 (01):
  • [32] Pan-Influenza A Protection by Prime-Boost Vaccination with Cold-Adapted Live-Attenuated Influenza Vaccine in a Mouse Model
    Jang, Yo Han
    Kim, Joo Young
    Byun, Young Ho
    Son, Ahyun
    Lee, Jeong-Yoon
    Lee, Yoon Jae
    Chang, Jun
    Seong, Baik Lin
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [33] The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study
    Flasche, Stefan
    Jit, Mark
    Rodriguez-Barraquer, Isabel
    Coudeville, Laurent
    Recker, Mario
    Koelle, Katia
    Milne, George
    Hladish, Thomas J.
    Perkins, T. Alex
    Cummings, Derek A. T.
    Dorigatti, Ilaria
    Laydon, Daniel J.
    Espana, Guido
    Kelso, Joel
    Longini, Ira
    Lourenco, Jose
    Pearson, Carl A. B.
    Reiner, Robert C.
    Mier-y-Teran-Romero, Luis
    Vannice, Kirsten
    Ferguson, Neil
    PLOS MEDICINE, 2016, 13 (11):
  • [34] Impact of vaccination of a high-risk population for Argentine hemorrhagic fever with a live-attenuated Junin virus vaccine
    Enria, DA
    Feuillade, MR
    Levis, S
    Briggiler, AM
    Ambrosio, AM
    Saavedra, MD
    Becker, JL
    Riera, L
    Calderón, G
    Pini, N
    Sottosanti, J
    Avilés, G
    García, J
    Sabattini, M
    EMERGENCE AND CONTROL OF RODENT-BORNE VIRAL DISEASES (HANTAVIRAL AND ARENAL DISEASES): EMERGING DISEASES, 1999, : 273 - 280
  • [35] Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine
    Belshe, RB
    Gruber, WC
    Mendelman, PM
    Cho, I
    Reisinger, K
    Block, SL
    Wittes, J
    Iacuzio, D
    Piedra, P
    Treanor, J
    King, J
    Kotloff, K
    Bernstein, DI
    Hayden, FG
    Zangwill, K
    Yan, LH
    Wolff, M
    JOURNAL OF PEDIATRICS, 2000, 136 (02): : 168 - 175
  • [36] Intranasal live-attenuated influenza vaccine (LAIV) is unlikely to cause egg-mediated allergic reactions in egg-allergic children
    Turner, Paul J.
    Erlewyn-Lajeunesse, Michel
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2015, 3 (02): : 312 - 313
  • [37] Early impact of the Australian national shingles vaccination program with the herpes zoster live attenuated vaccine
    Litt, John
    Booy, Robert
    Bourke, Debra
    Dwyer, Dominic E.
    Leeb, Alan
    McCloud, Philip
    Stein, Alicia N.
    Woodward, Michael
    Cunningham, Anthony L.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2020, 16 (12) : 3081 - 3089
  • [38] Intranasal live-attenuated vaccine primes influenza-specific B cells in local lymph nodes that are rapidly recalled with parental inactivated subunit vaccine boost
    Jegaskanda, S.
    Mason, R.
    Andrews, S.
    Wheatley, A.
    Zhang, R.
    Abambrozak, D.
    Santos, C.
    Luke, C.
    Matsuoka, Y.
    Brenchley, J.
    Talaat, K.
    Permar, S.
    Liao, H-X
    Koup, R.
    Roederer, M.
    McDermott, A.
    Subbarao, K.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2016, 46 : 594 - 594
  • [39] A PHASE I CLINICAL TRIAL EVALUATING THE IMPACT OF TETRAVALENT RECOMBINANT SUBUNIT DENGUE VACCINE BOOST ADMINISTERED TO SUBJECTS WHO HAVE PREVIOUSLY BEEN VACCINATED WITH A LIVE-ATTENUATED TETRAVALENT DENGUE VACCINE
    Coller, Beth-Ann G.
    Durbin, Anna
    Kirkpatrick, Beth
    Pierce, Kristen
    Grier, Palmtama
    Sabundayo, Beulah
    Larsson, Catherine
    He, Helen
    Sausser, Michele
    Russell, Amy
    Martin, Jason
    Sachs, Jeff
    Lee, Andrew W-T
    Stephanie, Villarreal
    Wang, Long
    Coren, Adel
    Traina, Stacey
    Whitehead, Stephen S.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2017, 95 (05): : 20 - 20
  • [40] Influenza A virus shedding reduction observed at 12 weeks post-vaccination when newborn pigs are administered live-attenuated influenza virus vaccine
    Kaiser, Troy J.
    Smiley, Rex A.
    Fergen, Brian
    Eichmeyer, Marc
    Genzow, Marika
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2019, 13 (03) : 274 - 278